Oncology Drug Funding is first of its kind funding intelligence report, which provides complete landscape on cancer drug funding starting from early, mid to late stage funding. Released in Sep 2013, it is largest focused updated data available, covering 321 active cancer-focused investors, with past 10 years investment details in more than 500 oncology-focused companies. Thus It will help to - First innovative report to provide insights on several new strategic/financial investors willing to fund your company’s growth. - Clearly identify - who will invest in your business and to which extent. - Quickly navigate the complete profiles of new and focused Investors and their investment strategies. - Identify the extent of funding in each round/series to meet your immediate and future needs. - To design and negotiate on better financial plans to unlock the real value of innovation/assets. - Directly get in touch with oncology focused Venture Partner through their Linkedin & E-mail ID. - Explore Top Investors and eliminate your hours of digital search and data curation. - Access to Numerous deals, structure & size to analyze true value of business model.

1. PRIVATE EQUITY
VENTURE CA
SEED FUND
GRANTSSERIES A
IPOMERCHANT BANKERGRANTS
MEZZANINE FINANCEPRIVATE EQUITY
INVESTOR
FINANCE
SERIES B
Opportunities
IDENTIFY NEW FUNDING
In Cancer Drug Development
Copyright © HH Biotechnologies Pvt. Ltd.

2. A Comprehensive Intelligence Report On
ONCOLOGYDRUG
FUNDING
2013
REPORT COVERS ‘ONCOLOGY FOCUSED’
321
502
947
3000+
Active Venture Capital Firm Profiles
Investment Size | Criteria | Geographic focus
Company Funding Details
Includes past 10 years all Major Investment Rounds/Series
Venture Partners Professional Profiles
Linkedin & Email IDs of Partners | Personal Assistants Email IDs / Contact details
Funding Round Details
Details of Series A | B | C | D | E | F Included
Infographics Based Summary
Quick explore the Geographic distribution of VCs & their Geographic preference of
funding w.r.t USA, Europe & Asia.6 pages
VENTURE CAPITAL
PRIVATE EQUITY
PRIVATE EQUITY
VEN
SEED FUND
G
S
MERCHANT BANKER GRANTSMEZZANINE FINANCE
FINANCEIPO
COMPREHENSIVE
INTELLIGENCE
SERIES2
Copyright © HH Biotechnologies Pvt. Ltd.

3. Oncology Drug Funding 2013 is first of its kind funding intelligence report, which provides complete
landscape on cancer drug funding starting from early, mid to late stage fundings. It brings more
authentic data under evaluation and is designed in a manner to keep knowledge intact, clear and
precise. It also offers quick navigation on past 10 years major investments in the domain, thus allowing
the information on fingertips’ and enhances your drug funding in-depth understanding. Further any
information duplication is avoided to provide you with a clear and actionable intelligence.
Full Coverage
• One of the largest updated data available, covering 321 active cancer-focused investors with their investment
details in more than 500 oncology-focused companies.
• Includes Active Venture Capital, Private Equity and some notable Angel Investor firms.
• Also includes individual Investor Company profile, their core oncology venture partner team details &
Investor funding preferences & past investments.
Complete Cancer Drug Investors Intelligence
• With quick navigation tables, easily identify the top investors and their rich investment portfolio.
• Identify where large investors are investing in; and easily predict their funding preferences.
• Within oncology funding space, identify individual investor’s inclination towards funding drugs, diagnostics
or risky technologies.
Identify Top Investors
• Worldwide coverage of 500+ companies including cancer drug discovery/development, cancer diagnostic
and cancer device/technology companies.
• Past 10 years complete funding data including various follow-up funding round/series details.
• Navigation Table to identify various funding Exits; through IPO or M&A activities.
• Quick all sets of funding from Seed to Growth are covered.
All at One Place
PRIVATE EQUITY
ANGEL INVESTOR
VENTURE CAPITA
PRIVAT
PRIVATE EQUITY
NTURE CAPITAL
D MERCHANT B
SEED FU
SEED FUND
FINANCE
PARTNER
FINANCE
GRANTS
GRANTS
MEZZANINE FINANCEIPO
SERIES B
SERIES A
IPO
GROWTH FUND SERIES A
MERCHANT BANKER
Largest Oncology Funding Database with
Oncology focused Venture Partner’s Profiles.
3
ONCOLOGY
DRUG
FUNDING
www.omicsx.com/reports.html

4. 12 Pages Infographics and Table,
describes worldwide distribution
of 321 Active Oncology Drug
Funding Firms, with their
country wise location, assets
size, geographic investment
preferences, ideal investment
range and investment focus
towards –early, mid and late stage
funding.
33Pages Infographics and Tables,
provides the complete insights of
oncology funding pattern in past
10 years in 449 cancer focused
companies, with geographic
emphasis on investments in Exit
(through IPO/M&A) and Active
companies. Navigation tables
for Exit and Active companies to
provide list of all major funding
rounds and their investors.
502 Pages contain 321 active
oncology focused investor firms
profilescoveringdetailsofcontact,
Funds under management, Total
investment portfolio Vs. cancer
focused investment portfolio,
geographicinvestmentpreference
and investment range.
Individual Firm management
profiles of key oncology focused
venture partners, e-mail/LinkedIn
contact details. Firm’s all major
oncology focused investments,
series/rounds details with list of
co-investors.
SECTIONSECTION
SECTIONSECTION
SECTIONSECTIONReport Structures
The complete 570 pages report is divided in three main sections
for easy and quick navigation within report. Report sections
contains thousands of interlinks to reach desired information
on a single click. Apart, Table A.1, B.1 & B.2 are quite beneficial
in narrowing down the choice of investors and identifying
individual companies funding history.
VENTURE CAPITAL
PRIVATE EQUITY
PRIVATE EQUITY
VEN
SEED FUND
G
S
MERCHANT BANKER GRANTSMEZZANINE FINANCE
FINANCEIPO
COMPREHENSIVE
INTELLIGENCE
SERIES4
Copyright © HH Biotechnologies Pvt. Ltd.

5. How this Report can Help
PRIVATE EQUITY
ANGEL INVESTOR
VENTURE CAPITA
PRIVAT
PRIVATE EQUITY
NTURE CAPITAL
D MERCHANT B
SEED FU
SEED FUND
FINANCE
PARTNER
FINANCE
GRANTS
GRANTS
MEZZANINE FINANCEIPO
SERIES B
SERIES A
IPO
GROWTH FUND SERIES A
MERCHANT BANKER
• First innovative report to provide insights on several new strategic/financial investors willing to fund your
company’s growth.
• Identify key venture partners contribution and strategic positions on Company’s Board.
• Detailed series co-investors details to identify best investors consortium for your needs.
• Access to Numerous deals, structure & size to analyze true value of business model.
CXOs / Directors / VPs
• Identify new emerging players in drug funding, with their core team and funding preferences.
• De-risk the venture by getting real insights through a comprehensive picture.
• Infographics design with focused and interactive content, takes no time in filling knowledge gaps.
• Virtually cover all oncology focused funding deals occurs in past 10 years with their valuation sizes.
Venture Partners
• Clearly identify - who will invest in your business and to which extent.
• Quickly navigate the complete profiles of focused Investors and their investment strategies.
• Identify the extent of funding in each round/series to meet your immediate and future needs.
• To design and negotiate on better financial plans to unlock the real value of innovation/assets.
• Directly get in touch with oncology focused Venture Partner through Linkedin & E-mail ID.
Start-ups / Entrepreneurs
• Explore Top Investors and eliminate your hours of digital search and data curation.
• Spend quality time in analyzing finer funding details & decisions making.
• Identify paradigm shift in oncology drug funding; with 10 years of funding history covering 500+ companies
and 3000+ Deals.
• Closely monitor wining deals and M&A activities by bringing more data under analysis.
Analysts/ Consultants
A Perfect Guide to provide complete
Landscape on Oncology Drug Funding.
5
ONCOLOGY
DRUG
FUNDING
www.omicsx.com/reports.html

6. VENTURE CAPITAL
PRIVATE EQUITY
P
VENTURE C
SEED FUND
GRANTS
SERIES A
IPO
MERCHANT BANKER GRANTSMEZZANINE FINANCE
FINANCEIPO
YES, I WOULD LIKE TO PURCHASE NOW
Your Details: (Please use BLOCK CAPITALS)
Title: Dr Mr Ms
First Name:__________________________________________________
Last Name:___________________ Middle Name:____________________
Department:_________________________________________________
Position:_____________________________________________________
Company:____________________________________________________
Address:_____________________________________________________
___________________________________________________________
____________________________State/Province___________________
Country:_____________________Postcode/Zip:____________________
Tel:____________________________ Fax:_________________________
Mobile No:__________________________________________________
Email:_______________________________________________________
Please sign below to confirm your order
Date: ___________ Signature______________________________________
Product Type: Intelligence Report (570 pages)
Published by: HH Biotechnologies Pvt. Ltd.
Product Code: ODF2013
Published in: September 2013
Single user price: $1495.00
Online Purchases: Click Here
Payment
To pay by Credit Card (PayPal, Visa, MasterCard, American Express), please, click ‘BUY NOW’ button on repot page
http://omicsx.com/reports.html
Mail this completed
order form to:
HH Biotechnologies Pvt. Ltd.
2760,Link Road,
Nunhai Industrial Area,
Near Rambagh,
Agra-282006 India.
E-mail: reports@omicsx.com
Online: www.omicsx.com
Fax back this form to
USA +1 646 568 9962
Asia +91 562 228 1099
If you want to order Corporate
License or Hard Copy, please,
contact our Customer Service:
contact@omicsx.com
Stay Legal: Terms &
Conditions
In placing an order you agree
not to hand-on or otherwise
communicate this report in
whole or part to any 3rd party
whatsoever by any means or
any access. You firstly pay for
report, then I provide it.
Our full terms and conditions
related to the sale of this
report please click here....
(All orders must be signed by authorised signatory)
Sales Contact Numbers
USA +1 646 513 4433
UK +44 203 608 3536
Asia +91 562 228 1122
Product Name: A Comprehensive Intelligence Report On - Oncology Drug Funding 2013
Order Form
Copyright © HH Biotechnologies Pvt. Ltd.